Search News Archives
Special Offers and Promotions
Conferences | Events
TTP plc enters into exclusive licence agreement with DiaSorin to commercialise molecular diagnostics platform
TTP plc (TTP), a leading independent technology and product development company, and DiaSorin, a global leader in the in vitro diagnostic (IVD) field, have signed an exclusive licence and technology transfer agreement.
DiaSorin will combine its extensive molecular test offering with TTP’s Puckdx™ platform to develop a single-use, sample-to-answer, molecular diagnostics point-of-care platform for human IVD applications.
TTP’s proprietary Puckdx platform offers a flexible, fast time-to-result and low-cost solution for translating diagnostic assays for human and animal health and life science research to an easy-to-use desktop device. TTP’s Puckdx is based on a unique disposable robotic pipette system with a fast PCR module, combined with a cartridge containing all the necessary reagents.
Using this simple and cost-effective technology solution in combination with DiaSorin’s human IVD assays could provide clients with a result in less than 15 minutes. This could help to decentralise testing, which in turn could make diagnostic services more affordable and convenient for patients and reduce the time from diagnosis to treatment to help prevent the spread of infectious diseases.
Giles Sanders, Consultant at TTP plc said: “We are delighted that DiaSorin has chosen Puckdx as their preferred POC platform. We look forward to working in close partnership with DiaSorin to rapidly commercialise the platform, benefiting patients and healthcare providers worldwide.”
Piers Harding, Consultant at TTP plc added: “During the development of the Puckdx platform we have focussed on a system that enables easy transfer of assays and a reliable and readily manufactured disposable. We are excited to have such a major diagnostic company wishing to bring the platform to market for human applications. The opportunity to utilise Puckdx for other fields of application continues to be available and we would be keen to collaborate with key players developing assays in areas such as for animal health and low-cost lab robotics”.
TTP’s Puckdx platform is based on a unique disposable robotic pipette system with a fast PCR module, combined with an easy-to-use cartridge containing all the necessary reagents.
Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years the Company has been developing, producing and marketing reagent kits for IVD worldwide.
Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist.”
TTP is an independent technology company where scientists and engineers collaborate to invent, design and develop new products and technologies. Working across a wide spectrum of industries including health, telecoms, industrials and consumer, TTP creates breakthrough solutions that bring strong commercial value to clients and the benefits of technology to all.